United States

Celgene Corp (CELG.O)

CELG.O on Nasdaq

23 Feb 2017
Change (% chg)

$0.19 (+0.16%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for CELG.O


Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology... (more)


Beta: 1.76
Market Cap(Mil.): $92,935.88
Shares Outstanding(Mil.): 777.97
Dividend: --
Yield (%): --


  CELG.O Industry Sector
P/E (TTM): 48.05 44.59 29.71
EPS (TTM): 2.49 -- --
ROI: 7.98 -3.18 12.94
ROE: 31.94 5.86 14.09

BRIEF-Celgene announces retirement of president and COO Jacqualyn Fouse

* Celgene announces retirement of president and Chief Operating Officer, Jacqualyn Fouse, Ph.D. And promotion of Scott Smith to president and chief operating officer Source text for Eikon: Further company coverage:

Feb 23 2017

BRIEF-FDA expands indication for Revlimid in multiple myeloma patients following auto-HSCT

* FDA expands indication for Revlimid® (lenalidomide) as a maintenance treatment for patients with multiple myeloma following autologous hematopoietic stem cell transplant (auto-HSCT)

Feb 22 2017

BRIEF-Celgene reports positive results from Phase III sunbeam trial of oral ozanimod in patients with relapsing multiple sclerosis

* Celgene announces positive results from Phase III sunbeam trial of oral ozanimod in patients with relapsing multiple sclerosis

Feb 17 2017

Celgene to pay $198.5 million to settle drug patent licensing case

Biopharmaceutical company Celgene Corp has agreed to pay $198.5 million to resolve a lawsuit accusing it of failing to pay royalties on patents for two drugs subject to a licensing agreement.

Feb 16 2017

BRIEF-Soros Fund Management takes in Facebook, ups in T Mobile and Alphabet

* Soros Fund Management takes share stake in facebook inc of 353,686 shares

Feb 14 2017

BRIEF-Neximmune acquired by group of investors led by former Celgene and Medtronic CEOs

* Acquired by a consortium of private investors led by former Celgene and Medtronic ceos Source text for Eikon:

Feb 14 2017

BRIEF-Celgene receives second subpoena relating to past inquiry - SEC filing

* Says received a second subpoena requesting materials primarily related to patient assistance to a past inquiry - sec filing

Feb 10 2017

Celgene renews bid to escape lawsuit over off-label marketing

Celgene Corp has asked a court to reconsider an order allowing a whistleblower lawsuit accusing it of promoting its cancer drugs Revlimid and Thalomid for off-label uses to go forward, saying a recent appeals court decision had raised the standard for the whistleblower's claims.

Feb 01 2017

BRIEF-Celgene receives positive CHMP opinion to expand REVLIMID indication

* Celgene receives positive CHMP opinion to expand REVLIMID (lenalidomide) indication as monotherapy for the maintenance treatment of patients with newly diagnosed multiple myeloma (mm) after autologous stem cell transplantation

Jan 27 2017

BRIEF-Celgene CEO says tax reform could provide significant benefit to U.S. economy, healthcare industry - Conf Call

* Celgene says Q4 topline growth was predominantly volume driven with 14 percent of growth coming from product volume: Conf Call

Jan 26 2017

More From Around the Web


  Price Chg
Takeda Pharmaceutical Co Ltd (4502.T) ¥5,349 +12.00
Eisai Co., Ltd (4523.T) ¥6,306 +65.00
Johnson & Johnson (JNJ.N) $122.17 +0.47
Novartis AG (NOVN.S) CHF77.15 -0.45
Pfizer Inc. (PFE.N) $34.06 --
Roche Holding Ltd. (ROG.S) CHF245.10 --
Roche Holding Ltd. (RO.S) CHF246.20 -2.00
Merck & Co., Inc. (MRK.N) $65.83 -0.02
Sanofi SA (SASY.PA) €80.58 +0.45
AstraZeneca plc (AZN.L) 4,607.00 +6.50

Earnings vs. Estimates